Amgen Inc Quick Ratio (AMGN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amgen Inc   (NASDAQ: AMGN)

Amgen Inc 's Quick Ratio

AMGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Amgen Inc 's Cash & cash equivalent grew by 127.65 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Amgen Inc 's Quick Ratio to 1.07, Quick Ratio remained below Amgen Inc average.

Within Biotechnology & Pharmaceuticals industry 112 other companies have achieved higher Quick Ratio than Amgen Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2711, from total ranking in the first quarter 2026 at 3620.

Explain Quick Ratio?
How much Cash & cash equivalents AMGN´s has?
What are AMGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMGN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 24.55 % 8.46 % 10.35 % 7.28 % -4.84 %
Y / Y Cash & cash equivalent Change 241.36 % 36.64 % -23.75 % 4.82 % -13.69 %
Quick Ratio MRQ 1.07 0.48 0.36 0.43 0.39
AMGN's Total Ranking # 2711 # 3620 # 3229 # 3389 # 3434
Seq. Current Liabilities Change 2.19 % -2.1 % 16.97 % 6.42 % -11 %
Seq. Cash & cash equivalent Change 127.65 % 31.87 % -3.35 % 17.65 % -8.88 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 113
Healthcare Sector # 614
Overall Market # 1911


Quick Ratio Statistics
High Average Low
5.05 2.05 0.36
(Sep 30 2017)   (Dec 31 2025)




Financial Statements
Amgen Inc 's Current Liabilities $ 25,502 Millions Visit AMGN's Balance sheet
Amgen Inc 's Cash & cash equivalent $ 27,404 Millions Visit AMGN's Balance sheet
Source of AMGN's Sales Visit AMGN's Sales by Geography


Cumulative Amgen Inc 's Quick Ratio

AMGN's Quick Ratio for the trailling 12 Months

AMGN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 12.48 % 5.43 % 7.23 % 5.27 % 7.82 %
Y / Y Cash & cash equivalent TTM Growth 53.39 % -1.16 % -11.45 % -1.82 % -41.54 %
Quick Ratio TTM 0.59 0.42 0.39 0.43 0.44
Total Ranking TTM # 2176 # 2603 # 1883 # 1883 # 1896
Seq. Current Liabilities TTM Growth 5.42 % 2.15 % 2.7 % 1.7 % -1.18 %
Seq. Cash & cash equivalent TTM Growth 50.14 % 9.12 % -7.43 % 1.15 % -3.26 %

Quick ratio ranking by company, industry and sector >> Back to AMGN Financial Strength Comparisons >> Go to Compare AMGN Quick Ratio to its Competitors

On the trailing twelve months basis AMGN Cash & cash equivalent more than doubled by 241.36 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Amgen Inc 's Quick Ratio to 0.59, Quick Ratio remained below AMGN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Amgen Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3934.

Explain Quick Ratio?
How much Cash & cash equivalents AMGN´s has?
What are AMGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 903
Within the Market # 2711


trailing twelve months Quick Ratio Statistics
High Average Low
2.86 1.02 0.29
(Mar 31 2015)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Autolus Therapeutics Plc  2.93 $ 201.630  Millions$ 68.790  Millions
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions

Date modified: 2026-09-13T23:23:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.